Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
J Neuroimmunol ; 110(1-2): 57-65, 2000 Oct 02.
Article in English | MEDLINE | ID: mdl-11024534

ABSTRACT

beta-Adrenoceptor (betaAR) expression and function as well as its modulation via intracellular transduction signals, were analyzed on the T cell lymphoma BW5147. Independently to the kinetic of proliferation and relative to the number of receptors displayed in normal T lymphocytes, BW5147 cells displayed a decreased number of betaAR, uncoupled to adenylate cyclase, but coupled to protein kinase C stimulation. This last effect was impaired by a beta-antagonist and by blockers of the enzymatic pathways involved in T lymphocyte proliferation, inducing a recovery of betaAR sites. Down-regulation of betaAR would implicate the loss of a negative neuroimmune control mechanism for lymphocyte proliferation. The coupling of the remaining sites to a positive signal for cellular activation, would contribute to establish an hyperproliferative state.


Subject(s)
Protein Kinase C/metabolism , Receptors, Adrenergic, beta/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/enzymology , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/pharmacology , Adenylyl Cyclases/metabolism , Adrenergic beta-Agonists/pharmacology , Cell Division/drug effects , Cell Division/immunology , Enzyme Activation/immunology , Enzyme Inhibitors/pharmacology , Humans , Indoles/pharmacology , Isoproterenol/pharmacology , Lymphoma, T-Cell , Maleimides/pharmacology , Neuroimmunomodulation/immunology , Protein Kinase C/antagonists & inhibitors , Signal Transduction/drug effects , Signal Transduction/immunology , T-Lymphocytes/immunology , Tumor Cells, Cultured
2.
Cell Mol Neurobiol ; 20(3): 255-68, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10789827

ABSTRACT

1. The aim of the present work was to determine hypoxia-induced modifications in the cascade of intracellular events coupled to muscarinic acetylcholine receptor (mAChR) activation in brain. For this purpose, enzymatic activities were measured on normoxically incubated frontal cortical slices from mice exposed to hypobaric hypoxia for 72 hr. 2. We found that hypoxia induced alterations in several cerebral enzymatic basal activities: it increased nitric oxide synthase (NOS), but it decreased both membrane protein kinase C (PKC) and phospholipase C activities. 3. The mAChR agonist carbachol was found to increase phosphoinositide hydrolysis to greater values in hypoxic tissues than those found in normoxic conditions. Furthermore, a greater translocation of PKC in response to carbachol was observed in hypoxic tissues than in normoxic ones. 4. Besides, carbachol induced a drastic reduction of NOS activity in hypoxic brains, at concentrations that stimulated this enzyme activity in normoxic preparations. In the latter, inhibition is obtained only with high concentrations of the cholinergic muscarinic agonist. 5. These results pointed to a carbachol-mediated mAChR hyperactivity induced by hypoxic insult. 6. The possibility that these effects would account for a compensatory mechanism to diminish NOS hyperactivity, probably protecting for NO neurotoxic action in hypoxic brain, is also discussed.


Subject(s)
Frontal Lobe/physiology , Hypoxia, Brain/physiopathology , Phenylcarbamates , Receptors, Muscarinic/physiology , Signal Transduction/physiology , Air Pressure , Animals , Atropine/pharmacology , Carbachol/pharmacology , Carbamates/pharmacology , Chelating Agents/pharmacology , Cholinergic Agonists/pharmacology , Egtazic Acid/analogs & derivatives , Egtazic Acid/pharmacology , Enzyme Inhibitors/pharmacology , Frontal Lobe/cytology , Mice , Mice, Inbred Strains , Muscarinic Antagonists/pharmacology , Neurons/chemistry , Neurons/drug effects , Neurons/enzymology , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type I , Phosphatidylinositols/metabolism , Phosphodiesterase Inhibitors/pharmacology , Protein Kinase C/metabolism , Receptor Cross-Talk/physiology , omega-N-Methylarginine/pharmacology
3.
Can J Physiol Pharmacol ; 77(1): 22-8, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10535662

ABSTRACT

In addition to its effect on D2 dopamine receptor blockades, haloperidol is able to interact with multiple neurotransmitters (NTs). Its action on phosphoinositide (PI) turnover was studied on cerebral cortex preparations. It induces an increase in inositol phosphate (IP) accumulation, which was only blunted by the alpha1-adrenoceptor blocker prazosin. Haloperidol maximal effect (Emax) was less than the effect of the full agonist norepinephrine (NE), and dose-response curves for both NE in the presence of submaximal doses of haloperidol and haloperidol in the presence of Emax doses of NE showed that haloperidol behaves as a partial agonist of cerebral alpha1-adrenoceptors. Its effect on PI hydrolysis is mediated through phospholipase C activation, as 2-nitro-4-carboxyphenyl-N,N-diphenylcarbamate (NCDC) and 1-[6-([(17beta)-3-methoxyestra- 1,3,5(10)-trien-17-yl]amino)hexyl]-1H-pyrrole-2,5-dione) (U-73122) were able to abrogate both haloperidol and NE actions. Further, the typical neuroleptic exerts a direct activation of alpha1-adrenoceptors as its actions were not modified by cocaine and persisted in spite of chemical rat cerebral denervation with 6-hydroxydopamine (6-OHDA). The possibility that this agonistic action on alpha1-adrenoceptors would be involved in haloperidol side effects is also discussed.


Subject(s)
Antipsychotic Agents/pharmacology , Frontal Lobe/drug effects , Haloperidol/pharmacology , Phosphatidylinositols/metabolism , Receptors, Adrenergic, alpha-1/drug effects , Animals , Dose-Response Relationship, Drug , Female , Hydrolysis , Norepinephrine/pharmacology , Rats , Rats, Wistar , Type C Phospholipases/metabolism
4.
Cell Signal ; 11(4): 293-300, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10372807

ABSTRACT

The induction of intracellular signals coupled to alpha1-adrenoceptor by haloperidol, were studied in rat cerebral frontal cortex. The neuroleptic exerts a biphasic effect on nitric oxide synthase (NOS), inhibiting the enzymatic activity at low concentrations (10(-9) M), while higher concentrations (10(-5) M) increased it. Protein kinase C (PKC) and phosphoinositol turnover (PIs) were involved in these actions, as haloperidol induced PKC translocation at low concentrations, and increased PIs turnover at high concentrations. All the effects of haloperidol were blocked by the alpha-adrenoceptor antagonist prazosin and the phospholipase C (PLC) inhibitor NCDC. The possibility that a cross-talk between both enzymatic pathways depending on the neuroleptic concentration used in rat cerebral frontal cortex, is also discussed.


Subject(s)
Adrenergic alpha-1 Receptor Agonists , Frontal Lobe/metabolism , Haloperidol/pharmacology , Signal Transduction , Adrenergic alpha-1 Receptor Antagonists , Animals , Culture Techniques , Frontal Lobe/drug effects , Inositol Phosphates/metabolism , Intracellular Fluid/metabolism , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type I , Protein Kinase C/metabolism , Rats
5.
Synapse ; 31(2): 151-3, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10024012

ABSTRACT

Previously, we demonstrated that gamma vinyl-GABA (GVG, Vigabatrin) dose-dependently inhibits cocaine-induced increases in dopamine (DA) concentrations in both the rodent and primate brain. Furthermore, it abolishes cocaine self-administration and conditioned place preference, while having no effect on locomotor activity or drug delivery to the brain. In an effort to better understand the mechanisms underlying this inhibition, we examined the effect of the selective GABA(B) receptor antagonist SCH 50911 on the GVG-induced decrease in cocaine's elevation of extracellular DA concentrations in the nucleus accumbens (NACC). Cocaine administration alone (20 mg/kg i.p.) produced a 480% increase in extracellular NACC DA levels. GVG (300 mg/kg i.p.) significantly reduced this increase by 25% (P<0.01). In sharp contrast, extracellular DA levels increased to 550% after the sequential administration of SCH 50911 (3 mg/kg i.p.), GVG, and cocaine. This increase is significantly different than GVG and cocaine (P<0.05) but similar to cocaine alone. These results demonstrate that the GABA(B) antagonist SCH 50911 was able to completely abolish GVG's inhibition of cocaine-induced increases in DA in the NACC and implicates the GABA(B) receptor in the mechanism underlying this inhibition.


Subject(s)
Cocaine/pharmacology , Dopamine Uptake Inhibitors/pharmacology , Dopamine/metabolism , Enzyme Inhibitors/pharmacology , Nucleus Accumbens/drug effects , Receptors, GABA-B/drug effects , gamma-Aminobutyric Acid/analogs & derivatives , Animals , GABA Antagonists/pharmacology , Male , Morpholines/pharmacology , Nucleus Accumbens/metabolism , Rats , Rats, Sprague-Dawley , Receptors, GABA-B/metabolism , Vigabatrin , gamma-Aminobutyric Acid/pharmacology
6.
J Neural Transm (Vienna) ; 105(2-3): 193-204, 1998.
Article in English | MEDLINE | ID: mdl-9660097

ABSTRACT

Biochemical signalling events coupled to muscarinic cholinergic receptors (mAChR), specifically those related to nitric oxide (NO) production, were studied on rat cerebral frontal cortex. The mAChR agonist carbachol was found to exert a specific biphasic action on NO synthase (NOS) activity: low doses ranging between 10(-9) M to 10(-7) M lead to NOS activation while higher doses (>10(-6) M) inhibited enzymatic activity. Carbachol stimulatory action was blunted by agents that interfere with calcium-calmodulin while a protein kinase (PKC) inhibitor, staurosporine was able to abrogate the inhibitory effect. Moreover, PKC activity showed maximum translocation to cerebral frontal cortex membranes with carbachol concentrations that inhibited NO production. Products from phosphoinosite (PI) hydrolysis are involved in these actions as carbachol was found to increase PI turnover in a dose dependent manner. These results would serve as an example of cross-talk between both enzymatic pathways.


Subject(s)
Brain Chemistry/physiology , Nitric Oxide/physiology , Receptors, Muscarinic/metabolism , Signal Transduction/physiology , Animals , Carbachol/pharmacology , Dose-Response Relationship, Drug , Enzyme Activation/drug effects , In Vitro Techniques , Inositol Phosphates/metabolism , Muscarinic Agonists/pharmacology , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type I , Prefrontal Cortex/drug effects , Prefrontal Cortex/enzymology , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/metabolism , Rats
7.
Article in English | MEDLINE | ID: mdl-9339247

ABSTRACT

As several side effects of neuroleptics would be related to their interactions with several neurotransmitter receptors (R) haloperidol action on muscarinic cholinergic (mACh) R on frontal cerebral cortex preparations was analyzed. Here we show that haloperidol was able to inhibit in a concentration dependent manner the binding of specific mAChR radiolabeled antagonist on cerebral cortex membranes. This effect would be related to its interaction on mAChR of the M1 subtype as haloperidol blocked the stimulation of phosphoinositides (PIs) turnover induced by low concentrations of carbachol similarly as the M1 antagonist pirenzepine. However at high carbachol concentrations haloperidol triggered a potentiating stimulation of PIs hydrolysis that was only blocked by the alpha 1 adrenergic antagonist prazosin indicating an alpha 1 agonistic action of haloperidol on these Rs. These multireceptor actions of haloperidol found "in vitro" would strengthen its association with "in vivo" neuroleptic-induced side effects.


Subject(s)
Antipsychotic Agents/pharmacology , Cerebral Cortex/drug effects , Haloperidol/pharmacology , Muscarinic Antagonists , Receptors, Muscarinic/drug effects , Animals , Binding Sites , Carbachol , In Vitro Techniques , Inositol Phosphates , Muscarinic Agonists , Quinuclidinyl Benzilate , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...